Identification of a novel phage targeting methicillin-resistant Staphylococcus aureus In vitro and In vivo

Ji, Jiawei; Liu, Qian; Wang, Rui; Luo, Tingting; Guo, Xia; Xu, Mengsha; Yin, Qinyan; Wang, Xuetong; Zhou, Min; Li, Min; He, Ping

doi:10.1016/j.micpath.2020.104317

Cited by 23 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in combination with oxides or antibiotics, the phage is capable of a 3-log reduction in bacterial load within 24 h ( Li et al, 2021 ). The ability of a phage to inhibit MRSA infection of skin wounds in a murine model was investigated by Ji et al (2020) . Infection was induced by subcutaneous injection of the MRSA strain, and following 1 h, phage VB_SauS_SHSt was administered.…”

Section: Phagesmentioning

confidence: 99%

“…Infection was induced by subcutaneous injection of the MRSA strain, and following 1 h, phage VB_SauS_SHSt was administered. An increased inflammatory response was observed in the untreated group, with the treated group experiencing faster wound rehabilitation and reduced tissue damage ( Ji et al, 2020 ). A rat model was used to determine the efficacy of a recombinant nano phage in treating MRSA ATCC 33591-infected 3 rd degree wounds.…”

Section: Phagesmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Phage- and Bacteriocin-Based Therapies in Combatting Nosocomial MRSA Infections

Walsh

Johnson

Hill

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Staphylococcus aureus is a pathogen commonly found in nosocomial environments where infections can easily spread - especially given the reduced immune response of patients and large overlap between personnel in charge of their care. Although antibiotics are available to treat nosocomial infections, the increased occurrence of antibiotic resistance has rendered many treatments ineffective. Such is the case for methicillin resistant S. aureus (MRSA), which has continued to be a threat to public health since its emergence. For this reason, alternative treatment technologies utilizing antimicrobials such as bacteriocins, bacteriophages (phages) and phage endolysins are being developed. These antimicrobials provide an advantage over antibiotics in that many have narrow inhibition spectra, enabling treatments to be selected based on the target (pathogenic) bacterium while allowing for survival of commensal bacteria and thus avoiding collateral damage to the microbiome. Bacterial resistance to these treatments occurs less frequently than with antibiotics, particularly in circumstances where combinatory antimicrobial therapies are used. Phage therapy has been well established in Eastern Europe as an effective treatment against bacterial infections. While there are no Randomized Clinical Trials (RCTs) to our knowledge examining phage treatment of S. aureus infections that have completed all trial phases, numerous clinical trials are underway, and several commercial phage preparations are currently available to treat S. aureus infections. Bacteriocins have primarily been used in the food industry for bio-preservation applications. However, the idea of repurposing bacteriocins for human health is an attractive one considering their efficacy against many bacterial pathogens. There are concerns about the ability of bacteriocins to survive the gastrointestinal tract given their proteinaceous nature, however, this obstacle may be overcome by altering the administration route of the therapy through encapsulation, or by bioengineering protease-resistant variants. Obstacles such as enzymatic digestion are less of an issue for topical/local administration, for example, application to the surface of the skin. Bacteriocins have also shown impressive synergistic effects when used in conjunction with other antimicrobials, including antibiotics, which may allow antibiotic-based therapies to be used more sparingly with less resistance development. This review provides an updated account of known bacteriocins, phages and phage endolysins which have demonstrated an impressive ability to kill S. aureus strains. In particular, examples of antimicrobials with the ability to target MRSA strains and their subsequent use in a clinical setting are outlined.

show abstract

Section: Phagesmentioning

confidence: 99%

Section: Phagesmentioning

confidence: 99%

Efficacy of Phage- and Bacteriocin-Based Therapies in Combatting Nosocomial MRSA Infections

Walsh

Johnson

Hill

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…The morphological characteristics were observed under a transmission electron microscope (TEM, JEM-2000EX). For genomic analysis, total DNA was extracted from the high-titer phage Vp-9 (~ 10 10 PFU/ml) using the organic reagent method as described by Ji et al [7]. Phage genomic DNA sequencing was then performed using an Illumina high-throughput sequencing platform (Shanghai, China).…”

Section: Main Textmentioning

confidence: 99%

Genome sequence analysis of Vibrio parahaemolyticus lytic phage vP_VpaS_VP-RY-9

Ren

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

A lytic bacteriophage Vp-9, designated vP_VpaS_VP-RY-9, was isolated from sewage collected in Dalian, China. The double-stranded DNA genome of phage vP_VpaS_VP-RY-9 is 81.604 kb long, which has a mol% G + C content of 45.75, containing 117 ORFs, but any tRNA was found. Comparison of its genomic features and phylogenetic analysis revealed that phage vP_VpaS_VP-RY-9 is a novel member of the order Caudovirales, family Siphoviridae, genus Vibrio. The present results suggest that phage vP_VpaS_VP-RY-9 may represent a potential therapeutic agent against Vibrio parahaemolyticus.

show abstract

“…Staphylococcus phages belonging to the family of Siphoviridae have also been reported worldwide, however many of them display a lysogenic life cycle while sometimes also carrying virulence genes, both undesired characteristics for phage therapy. Several reports have shown the potential use of Staphylococcus phages alone or in combination with chemical antibiotics, for the penetration and removal of biofilms [11] and for the treatment of infections [12] .…”

Section: Introductionmentioning

confidence: 99%

Characterisation of bacteriophage JD419, a Staphylococcal phage with an unusual morphology and broad host range

Feng

Leptihn

Dong

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

As an antimicrobial therapy, therapeutic phages, also known as “Phage therapy” are able to inactivate multi-drug resistant bacteria such as methicillin and vancomycin resistant S. aureus and thus present a possible treatment for infections that are otherwise incurable. In this paper, we present a novel phage called JD419, which has a remarkably wide host-range. The virulent phage JD419 exhibits an elongated capsid and was able to infect and lyse 83 of all 129 tested clinical strains (64.3%) of multi-drug resistant S. aureus including MRSA. To evaluate the potential as a therapeutic phage, we tested the ability of phage JD419 to remain infectious after treatment exceeding physiological pH or temperature. The lytic activity of the phage was retained at pH values of 6.0-8.0 and at temperatures below 50°C. As phages sometimes contain virulence genes, we sequenced the complete genome of JD419. The 45509 bp genome contains a predicted 65 ORFs, none of which show homology to any known virulence or antibiotic resistance genes. Our study illustrates that Staphylococcus phage JD419 has the potential to be used for diagnostic, prophylaxic and therapeutic purposes.

show abstract

Identification of a novel phage targeting methicillin-resistant Staphylococcus aureus In vitro and In vivo

Cited by 23 publications

References 33 publications

Efficacy of Phage- and Bacteriocin-Based Therapies in Combatting Nosocomial MRSA Infections

Efficacy of Phage- and Bacteriocin-Based Therapies in Combatting Nosocomial MRSA Infections

Genome sequence analysis of Vibrio parahaemolyticus lytic phage vP_VpaS_VP-RY-9

Characterisation of bacteriophage JD419, a Staphylococcal phage with an unusual morphology and broad host range

Contact Info

Product

Resources

About